Masaru Matsuda Arcutis Biotherapeutics, Inc. (ARQT) insider trading activity

Masaru Matsuda is Officer of Arcutis Biotherapeutics, Inc.. Currently has a direct ownership of 181,373 shares of ARQT, which is worth approximately $1.85 Million. The most recent transaction as insider was on Nov 19, 2024, when has been sold 1,775 shares (Common Stock) at a price of $9.68 per share, resulting in proceeds of $17,182. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 181K

1.04% 3M change

288.93% 12M change

Total Value Held $1.85 Million

Masaru Matsuda Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Nov 19 2024	SELL Open market or private sale	$17,182 $9.68 p/Share	1,775 Reduced 0.97%	181,373 Common Stock
Nov 18 2024	BUY Grant, award, or other acquisition	-	4,875 Added 2.59%	183,148 Common Stock
Nov 04 2024	SELL Open market or private sale	$43,530 $8.68 p/Share	5,015 Reduced 2.74%	178,273 Common Stock
Aug 02 2024	SELL Open market or private sale	$47,084 $9.02 p/Share	5,220 Reduced 2.77%	183,288 Common Stock
May 28 2024	SELL Open market or private sale	$15,992 $9.01 p/Share	1,775 Reduced 0.93%	188,508 Common Stock
May 27 2024	BUY Grant, award, or other acquisition	-	4,875 Added 2.5%	190,283 Common Stock
May 02 2024	SELL Open market or private sale	$43,839 $8.74 p/Share	5,016 Reduced 2.63%	185,408 Common Stock
Mar 04 2024	SELL Open market or private sale	$41,811 $11.12 p/Share	3,760 Reduced 1.94%	190,424 Common Stock
Feb 13 2024	BUY Grant, award, or other acquisition	-	119,550 Added 38.11%	194,184 Common Stock
Jan 12 2024	BUY Grant, award, or other acquisition	-	28,000 Added 27.28%	74,634 Common Stock
Nov 21 2023	SELL Open market or private sale	$3,663 $1.98 p/Share	1,850 Reduced 3.82%	46,634 Common Stock
Nov 18 2023	BUY Grant, award, or other acquisition	-	4,875 Added 9.14%	48,484 Common Stock
May 31 2023	SELL Open market or private sale	$14,274 $7.8 p/Share	1,830 Reduced 4.16%	42,146 Common Stock
May 31 2023	BUY Grant, award, or other acquisition	$9,333 $6.38 p/Share	1,463 Added 3.25%	43,609 Common Stock
May 27 2023	BUY Grant, award, or other acquisition	-	4,875 Added 9.98%	43,976 Common Stock
Mar 02 2023	SELL Open market or private sale	$23,187 $16.17 p/Share	1,434 Reduced 7.34%	18,101 Common Stock
Mar 02 2023	BUY Grant, award, or other acquisition	-	21,000 Added 34.94%	39,101 Common Stock
Nov 21 2022	SELL Open market or private sale	$31,286 $18.19 p/Share	1,720 Reduced 8.09%	19,535 Common Stock
Nov 18 2022	BUY Grant, award, or other acquisition	-	4,875 Added 18.66%	21,255 Common Stock
Jun 02 2022	SELL Open market or private sale	$35,415 $19.73 p/Share	1,795 Reduced 9.88%	16,380 Common Stock
May 27 2022	BUY Grant, award, or other acquisition	-	4,875 Added 21.15%	18,175 Common Stock
Mar 03 2022	BUY Grant, award, or other acquisition	-	13,300 Added 50.0%	13,300 Common Stock

Also insider at

HALO

HALOZYME THERAPEUTICS, INC. Healthcare

SVP, General Counsel

Masaru Matsuda

Officer

San Diego, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ARQT shares.

Notify only if

Value

Insider Trading

Get notified when an Arcutis Biotherapeutics, Inc. insider buys or sells ARQT shares.

Notify only if

Operation

Value

Type

News

Receive news related to Arcutis Biotherapeutics, Inc.

Track Activities on ARQT

Account